#USA #Cell Therapy #Akadeum Life #microbubbles #New Orleans, Louisiana

Akadeum Life Sciences Showcases Microbubble Innovations at ASGCT 2025

Akadeum Life Sciences, renowned for its innovative buoyancy-based cell separation technology, is making significant strides in the field of cell therapies. At the upcoming American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, taking place from May 13 to 16 in New Orleans, the company will unveil its expanded capabilities surrounding microbubble technology. This upgrade promises to facilitate a seamless integration of microbubbles into existing cell and gene therapy platforms, significantly optimizing existing processes.

Microbubble technology, a cornerstone of Akadeum’s offerings, allows for more targeted and efficient cell separation. As Akadeum pushes forward, the latest iteration of their microbubble-based cell isolation kits — specifically designed for Human T Cell Leukopak separation — stands out as a pioneering solution. This process of cell isolation is not only the first of its kind to ensure minimal handling, resulting in healthier cells but also allows for both manual and automated 'in-bag' integration into laboratory workflows.

By leveraging this technology, researchers and clinicians can expect a reduction in both operational costs and physical space required for cell therapy manufacturing. The ability to perform centralized and decentralized therapies using a smaller footprint enhances efficiency without sacrificing quality. Furthermore, it opens avenues for high-throughput applications in cellular-based treatments.

Presentations at ASGCT

During the conference, several presentations are scheduled that will highlight the performance and benefits of Akadeum’s microbubble integrative techniques. One notable presentation will be led by Dr. Alex Sargent, the Director of Process Development for Cell and Gene Therapy at Charles River Laboratories. Scheduled for Thursday, May 15, at 5 PM CT, Dr. Sargent’s speech titled “Next Generation Cell Isolation: Replace Magnetics with Microbubbles” aims to present compelling data demonstrating how microbubbles can facilitate the manufacturing of T cells in a timely manner without compromising cell viability or phenotype.

Additionally, Lonza’s implementation of Akadeum’s Human T Cell Leukopak Isolation Kit on their Cocoon® Platform will be summarized during a poster viewing on the same day. With integration, Lonza has successfully achieved an increase in throughput and enhanced purity and viability metrics for CAR T therapy applications, ensuring reproducibility and desired cellular characteristics.

Further, Akadeum plans to share vital data on workflow integration in its Poster 1797 session on Thursday night, providing attendees a comprehensive look at how the technology fits within varied lab environments. At Booth #1748, interested parties can explore detailed protocols for cell separation directly from apheresis materials and learn how to effectively implement microbubbles with their current cell washing systems. Additionally, Akadeum offers an Evaluation Program, granting scientists firsthand access to the microbubble technology in their own laboratories under the guidance of an Akadeum expert.

Company Background

Akadeum Life Sciences is dedicated to advancing health through innovative separation technologies that improve cell isolation processes. Their mission is clear: to empower research and clinical breakthroughs in diagnostics, therapeutics, and foundational studies. With the upcoming showcase of their microbubble innovations, Akadeum continues to embody the spirit of innovation in the ever-evolving landscape of biotechnology and cell therapy.

For further updates and insights, visit Akadeum's website or follow them on LinkedIn, where they share their journey towards enhancing cell therapy solutions.